PMID- 15319266 OWN - NLM STAT- MEDLINE DCOM- 20050324 LR - 20131121 IS - 1524-4636 (Electronic) IS - 1079-5642 (Linking) VI - 24 IP - 10 DP - 2004 Oct TI - High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. PG - 1904-9 AB - OBJECTIVE: Protective properties of high-density lipoproteins (HDL) may include reverse cholesterol transport and suppression of oxidation and inflammation. These were investigated in vivo, as were the effects of HDL on the characteristics of atherosclerotic lesions. METHODS AND RESULTS: Male apolipoprotein E knockout (apoE-/-) and apoE-/- mice expressing human apolipoprotein AI (hAI/apoE-/-) were studied up to 20 weeks after commencing a high-fat diet. Plasma HDL cholesterol was twice as high in hAI/apoE-/- mice. Over time, aortic root lesion area remained less in hAI/apoE-/- mice, although plaques became complex. In advanced lesions, plaque lipid was higher in apoE-/- mice, whereas plaque collagen and alpha actin were increased in hAI/apoE-/- mice. In nonlesional aorta, mRNA abundance for pro-inflammatory proteins (vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule-1 [ICAM-1], monocyte chemoattractant protein-1 [MCP-1]) increased between 4 and 16 weeks in apoE-/- (but not wild-type) mice, and were not reduced by elevated HDL. Autoantibodies to malondialdehyde low-density lipoprotein (LDL) increased progressively in apoE-/- mice, with similar results in hAI/apoE-/- mice. CONCLUSIONS: HDL retarded plaque size progression despite greatly elevated plasma cholesterol. This effect was over a wide range of lesion severity. Expression of hAI reduced plaque lipid and increased the proportion of plaque occupied by collagen and smooth muscle cells, but did not affect indicators of inflammation or LDL oxidation. FAU - Choudhury, Robin P AU - Choudhury RP AD - Department of Medicine, Marc and Ruti Bell Program in Vascular Biology in the Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine, New York, NY 10016, USA. FAU - Rong, James X AU - Rong JX FAU - Trogan, Eugene AU - Trogan E FAU - Elmalem, Valerie I AU - Elmalem VI FAU - Dansky, Hayes M AU - Dansky HM FAU - Breslow, Jan L AU - Breslow JL FAU - Witztum, Joseph L AU - Witztum JL FAU - Fallon, John T AU - Fallon JT FAU - Fisher, Edward A AU - Fisher EA LA - eng GR - HL-61814/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20040819 PL - United States TA - Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology JID - 9505803 RN - 0 (Apolipoprotein A-I) RN - 0 (Apolipoproteins E) RN - 0 (Autoantibodies) RN - 0 (Chemokine CCL2) RN - 0 (Lipoproteins, HDL) RN - 0 (Lipoproteins, LDL) RN - 0 (RNA, Messenger) RN - 0 (Vascular Cell Adhesion Molecule-1) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - 4Y8F71G49Q (Malondialdehyde) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Animals MH - Apolipoprotein A-I/biosynthesis/blood MH - Apolipoproteins E MH - Arteriosclerosis/*prevention & control MH - Autoantibodies MH - Chemokine CCL2/metabolism MH - Cholesterol/blood MH - Humans MH - Inflammation/pathology MH - Intercellular Adhesion Molecule-1/metabolism MH - Lipoproteins, HDL/*physiology MH - Lipoproteins, LDL/immunology MH - Male MH - Malondialdehyde/immunology MH - Mice MH - Mice, Inbred C57BL MH - Neovascularization, Physiologic/*physiology MH - Oxidation-Reduction MH - RNA, Messenger/metabolism MH - Vascular Cell Adhesion Molecule-1/metabolism EDAT- 2004/08/21 05:00 MHDA- 2005/03/25 09:00 CRDT- 2004/08/21 05:00 PHST- 2004/08/21 05:00 [pubmed] PHST- 2005/03/25 09:00 [medline] PHST- 2004/08/21 05:00 [entrez] AID - 01.ATV.0000142808.34602.25 [pii] AID - 10.1161/01.ATV.0000142808.34602.25 [doi] PST - ppublish SO - Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1904-9. doi: 10.1161/01.ATV.0000142808.34602.25. Epub 2004 Aug 19.